In an evaluation of the safety and abuse research on the drug in hallucinogenic mushrooms, researchers suggest that if it clears phase III clinical trials, psilocybin should be re-categorized from a schedule I drug — one with no known medical potential — to a schedule IV drug such as prescription sleep aids, but with tighter control.